Xamoterol hemifumarateCAS# 73210-73-8 |
- Dacomitinib (PF299804, PF299)
Catalog No.:BCC3683
CAS No.:1110813-31-4
- AG-1478
Catalog No.:BCC3717
CAS No.:153436-53-4
- OSI-420
Catalog No.:BCC4472
CAS No.:183320-51-6
- Gefitinib hydrochloride
Catalog No.:BCC1591
CAS No.:184475-55-6
- Lapatinib Ditosylate
Catalog No.:BCC2083
CAS No.:388082-78-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 73210-73-8 | SDF | Download SDF |
| PubChem ID | 6440459 | Appearance | Powder |
| Formula | C36H54N6O14 | M.Wt | 794.8 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | ICI 118,587 | ||
| Solubility | Soluble to 50 mM in water and to 100 mM in DMSO | ||
| Chemical Name | (E)-but-2-enedioic acid;N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide | ||
| SMILES | C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | QEDVGROSOZBGOZ-WXXKFALUSA-N | ||
| Standard InChI | InChI=1S/2C16H25N3O5.C4H4O4/c2*20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19;5-3(6)1-2-4(7)8/h2*1-4,14,17,20-21H,5-12H2,(H,18,22);1-2H,(H,5,6)(H,7,8)/b;;2-1+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | β1-adrenoceptor-selective partial agonist (pA2 values are 7.4 - 7.8 and 5.2 - 6.2 at β1- and β2-adrenoceptors respectively). |
Xamoterol hemifumarate Dilution Calculator
Xamoterol hemifumarate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2582 mL | 6.2909 mL | 12.5818 mL | 25.1636 mL | 31.4545 mL |
| 5 mM | 0.2516 mL | 1.2582 mL | 2.5164 mL | 5.0327 mL | 6.2909 mL |
| 10 mM | 0.1258 mL | 0.6291 mL | 1.2582 mL | 2.5164 mL | 3.1454 mL |
| 50 mM | 0.0252 mL | 0.1258 mL | 0.2516 mL | 0.5033 mL | 0.6291 mL |
| 100 mM | 0.0126 mL | 0.0629 mL | 0.1258 mL | 0.2516 mL | 0.3145 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Baptifoline
Catalog No.:BCN7988
CAS No.:732-50-3
- (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin
Catalog No.:BCC6011
CAS No.:73168-24-8
- Effusol
Catalog No.:BCN2928
CAS No.:73166-28-6
- Fenticonazole nitrate
Catalog No.:BCC8983
CAS No.:73151-29-8
- Ferruginine
Catalog No.:BCN1911
CAS No.:73069-63-3
- Arecoline
Catalog No.:BCN8537
CAS No.:73069-28-9
- Scutebarbatine D
Catalog No.:BCN8536
CAS No.:910099-76-2
- Praeruptorin D
Catalog No.:BCN4990
CAS No.:73069-28-0
- (+)-Praeruptorin A
Catalog No.:BCN4989
CAS No.:73069-27-9
- Praeruptorin A
Catalog No.:BCN4987
CAS No.:73069-25-7
- Atractylenolide II
Catalog No.:BCN1044
CAS No.:73069-14-4
- Atractylenolide I
Catalog No.:BCN1043
CAS No.:73069-13-3
- Chloranthalactone E
Catalog No.:BCN7466
CAS No.:73215-92-6
- Remoxipride hydrochloride
Catalog No.:BCC6844
CAS No.:73220-03-8
- ITF2357 (Givinostat)
Catalog No.:BCC2150
CAS No.:732302-99-7
- Florfenicol
Catalog No.:BCC8984
CAS No.:73231-34-2
- Methylnaltrexone Bromide
Catalog No.:BCC1740
CAS No.:73232-52-7
- Moringin
Catalog No.:BCN7722
CAS No.:73255-40-0
- 5-O-Caffeoylshikimic acid
Catalog No.:BCN7929
CAS No.:73263-62-4
- 1,4-Dihydro-1,2-dimethyl-4-oxo-3-quinolinecarboxylic acid
Catalog No.:BCN1369
CAS No.:73281-83-1
- Deoxynojirimycin hydrochloride
Catalog No.:BCN2626
CAS No.:73285-50-4
- BAY 61-3606
Catalog No.:BCC1406
CAS No.:732983-37-8
- Methylnissolin
Catalog No.:BCN1368
CAS No.:733-40-4
- 3-Hydroxy-9,10-Dimethoxypterocarpan
Catalog No.:BCC8101
CAS No.:73340-41-7
The in vitro pharmacology of xamoterol (ICI 118,587).[Pubmed:2862938]
Br J Pharmacol. 1985 May;85(1):179-87.
The effect of xamoterol and (-)-isoprenaline have been compared for their activity at beta-adrenoceptor sites in a number of in vitro cardiac and smooth muscle preparations. Xamoterol produced weak positive chronotropic effects in guinea-pig, rat and cat atria (intrinsic activity less than 0.55, (-)-isoprenaline = 1). Positive inotropic effects were obtained in driven left atria of the cat but were absent in guinea-pig left atrial and right ventricular strip preparations. Agonistic effects were due to beta 1-adrenoceptor stimulation. Xamoterol was without beta-adrenoceptor-mediated inhibitory effects in guinea-pig ileal, tracheal and uterine preparations and in the rat vas deferens and oestrogen-primed uterus. Weak beta 2-adrenoceptor-mediated relaxation was obtained in progesterone-primed rat uteri. Xamoterol produced non-specific inhibitory effects in guinea-pig ileal and tracheal preparations. Xamoterol acted as a competitive antagonist at beta 1-(pA2 range = 7.4 to 7.8) and beta 2-adrenoceptors (pA2 range 5.2 to 6.2) and displaced [125I]-iodocyanopindolol from guinea-pig left atrial (pKD = 7.25) and uterine (pKD 5.24) membrane preparations. It is concluded that xamoterol displays a selective affinity for beta 1-adrenoceptors. Although its partial agonistic actions are more evident at beta 1-adrenoceptor sites, like prenalterol, xamoterol displays a degree of tissue rather than receptor-dependent selectivity.
The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.[Pubmed:6128041]
Br J Pharmacol. 1982 Oct;77(2):381-8.
1 In a preparation in which cardiovascular reflexes were prevented from occurring, ICI 118,587 (1-(p-hydroxyphenoxy)-3-beta-(morpholinocarbonamido) ethylamino-2-propranol fumarate) caused dose-dependent positive chronotropic and inotropic effects upon the dog heart. 2 The increase in heart rate brought about by ICI 118,587 was about 43% of the maximum increase produced by isoprenaline. 3 For a given chronotropic effect produced by either ICI 118,587 or isoprenaline, each compound produced a similar inotropic effect as indicated by an increase in LV dp/dtmax. 4 In contrast to the direct stimulant action of ICI 118,587 on the heart no direct effects on vascular smooth muscle were observed. 5 ICI 118,587 was shown to be a competitive antagonist of the chronotropic and vasodilator effects of isoprenaline on the heart and blood vessels and of the chronotropic effects of noradrenaline on the heart. 6 It is concluded that ICI 118,587 is a selective beta 1-adrenoceptor partial agonist.
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.[Pubmed:6115058]
J Med Chem. 1981 Mar;24(3):315-22.
Parallel series of 2-[(2-amidoethyl)amino]-1-arylethanols and 1-[(2-amidoethyl)amino]-3-(aryloxy)-2-propanols have been prepared, and the compounds were tested as beta-adrenoceptor stimulants on the heart and circulation of the dog. The corresponding 2-(alkylamino)-1-arylethanols and 3-(alkylamino)-2-propanols have been tested for comparison and the structure-activity relationships (SAR) examined. The arylethanols are potent full agonists, showing selectivity for the heart relative to blood vessels, while the (aryloxy)propanols are even more cardioselective and are partial agonists. Within a narrow series of 1-[(amidoethyl)amino]-3-(4-hydroxyphenoxy)-2-propanols, careful examination of the SAR of the amide group showed that great variation in cardioselectivity and degree of agonism may be produce. From this study ICI 118587, N-[20[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-4-morpholinecarboxamide, was selected for its high cardioselectivity and 50% agonist properties. This compound in under clinical evaluation as a cardiac stimulant.
